Viventia Bio, which is developing antibody drug conjugates for bladder and other cancers, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering.
The Winnipeg, Canada-based company, which was founded in 1995, plans to list on the Nasdaq under the symbol VITA. Viventia Bio filed confidentially on September 17, 2015. Leerink Partners, Cowen & Company and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
